Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G10 | O15496 | 2/20 | 0.32 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.32 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.32 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24304666 | 0.92 | PLA2G10 (0.32) | PLA2G10PLA2G1BPLA2G2APLA2G5 | |
| SCHEMBL25973653 | 0.91 | RPS6KB1 (0.30) | — | |
| SCHEMBL25973634 | 0.91 | PLA2G10 (0.31) | PLA2G10PLA2G1BPLA2G2APLA2G5 | |
| SCHEMBL25976851 | 0.91 | — | — | |
| SCHEMBL24304607 | 0.91 | — | — | |
| SCHEMBL25972298 | 0.90 | TBXAS1 (0.33) | PLA2G10PLA2G1BPLA2G2APLA2G5CYP3A4 | |
| SCHEMBL24305006 | 0.89 | P2RY10 (0.31) | — | |
| SCHEMBL25977097 | 0.89 | — | — | |
| SCHEMBL24304428 | 0.88 | — | — | |
| SCHEMBL25976961 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030904-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230250117-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030904-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | PLA2G10 31/4885PLA2G1B 22/4885PLA2G2A 29/4885 |
| US-20230250117-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | PHOSPHO1, SGMS2, SGMS1 | PLA2G10 31/4885PLA2G1B 22/4885PLA2G2A 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.